Delivery Order SPE2DB22D2206-SPE2DB25FHR08

Award Date 6/26/25
Potential Completion Date 6/27/25
Potential Value $1.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $14,243.78 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a diabetes treatment medication. The order has a completion date of May 27, 2025. Amerisourcebergen holds a substantial Indefinite Delivery Contract (IDC) valued at $999,999,999.00 with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the diabetes medication MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The $3,447.26 firm fixed-price contract has a completion date of May 22, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, providing a comprehensive vehicle for supplying a wide range of...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $17,177.62 firm fixed-price contract is for the delivery of the diabetes medication MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of April 18, 2025 and is not set aside for any specific business category. AmerisourceBergen holds a substantial $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,632.54 contract is for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of March 26, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a $1,088.36 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a medication used to treat diabetes. The delivery order has an ultimate completion date of June 27, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This is a $2,667.23 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a diabetes medication. The order has an ultimate completion date of June 24, 2025. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle through...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $5,441.80, is for the delivery of 4,568,078,553 units of the diabetes medication Mounjaro (12.5 mg/0.5 ml pen, 0.5 ml) with a performance period through April 30, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a...
This is a $40,769.66 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a diabetes medication. The contract has an ultimate completion date of July 10, 2025 and is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the diabetes medication MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,153.01 and a period of performance through April 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with DLA Troop Support Medical, valued at $999,999,999.00, which...
This is a $2,892.26 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a diabetes medication. The order has a completion date of July 8, 2025 and is not set aside for any particular business type. Amerisourcebergen Drug Corp is a for-profit organization that holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FHR08
    Delivery Order

This is a $1,904.63 firm fixed-price delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of the diabetes medication MOUNJARO 15 MG/0.5 ML PEN 0.5ML, with an ultimate completion date of June 27, 2025.

AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order contract is not designated as a set-aside and is part of the company's larger support of federal medical procurement needs, particularly for military and veteran healthcare systems.

Generated 9/25/25, 10:58 AM